Velocity Minerals Ltd. (TSX-V:VLC) (“Velocity” or the “Company”) announces that it has received Inferred Resource estimates for the Rozino gold deposit (“Rozino” or the “Project”), southeast Bulgaria.
Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
Here at the Investing News Network our mission is twofold; to provide the latest news and quality education by helping you identify investment opportunities in niche markets, and helping leading companies communicate their value to investors.
A market currently estimated to be worth $389 billion worldwide medical devices enjoyed a positive developing year in 2017. However, the issue of taxes is still present and played a role in the expectations for the market moving forward.
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.
Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. A long-time veteran of Amersham Health and
By Jocelyn Aspa
Mitel (NASDAQ:MITL; TSX:MNW) has announced the recognition of Frontier Communications (NASDAQ:FTR) as its leading US partner in 2016 and for the sixth consecutive year.
As quoted in the press release:
Frontier also received Mitel’s Top U.S. Service Provider award.
As a Mitel-Authorized Partner for 27 years, Frontier provides Mitel solutions to business customers
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today provided a shareholder update and highlighted the company’s recent achievements it has reached during the first part of
Q BioMed Inc. (OTCQB: QBIO) and ASDERA LLC today announce a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA’s ASD-002, which is being developed to treat a rare pediatric nonverbal disorder.
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced the Company closed a private placement with proceeds of $4,349,953.50. Laidlaw & Co (UK) Ltd. in New
BioSig Technologies (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced it has signed a ten-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration
From serums and masks to oral sprays and enriched waters, we’re counting down the novel ways in which some cannabis-based biotechs are entering this space.
By Pia Rivera
Reuters reported that Abbott Laboratories (NYSE:ABT) has offered concessions for its $25 billion bid for St. Jude Medical (NYSE:STJ).
As quoted in the article:
The move pushed back the European Commission’s decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer’s website on
St. Jude Medical shareholders approved the merger agreement under which Abbott (NYSE:ABT) will acquire St. Jude Medical.
The company warns that built up lithium deposits in their defibrillators’ batteries can cause them to short circuit.